Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients Journal of Neuroimmunology, 04/03/2012

Moberly JB et al. – The authors conducted an open–label, pilot study in 25 multiple sclerosis (MS) patients to assess the safety, pharmacokinetics, pharmacodynamics and exploratory efficacy of oral CS–0777, administered once weekly or every other week for 12weeks. CS–0777 resulted in a pronounced, dose–dependent decrease in lymphocytes and CD4 T cell subsets, which returned to baseline within 4weeks after the last dose. Overall, CS–0777 was safe and well–tolerated. These results require confirmation in a double–blind, placebo–controlled and adequately powered phase 2 study in MS.